Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

Botta, Cirino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.329
EU - Europa 1.137
AS - Asia 471
SA - Sud America 41
AF - Africa 16
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 4.004
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.286
IT - Italia 652
SG - Singapore 262
CN - Cina 126
DE - Germania 104
GB - Regno Unito 90
IE - Irlanda 64
CA - Canada 41
RU - Federazione Russa 40
BR - Brasile 32
AT - Austria 25
HK - Hong Kong 24
FI - Finlandia 20
NL - Olanda 20
EE - Estonia 19
FR - Francia 15
BE - Belgio 13
JP - Giappone 13
UA - Ucraina 13
IN - India 12
ES - Italia 11
SE - Svezia 11
CH - Svizzera 10
KR - Corea 6
UZ - Uzbekistan 6
CI - Costa d'Avorio 5
RO - Romania 5
TR - Turchia 5
CL - Cile 4
GR - Grecia 4
NZ - Nuova Zelanda 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AR - Argentina 3
AU - Australia 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
EG - Egitto 3
HU - Ungheria 3
ET - Etiopia 2
IQ - Iraq 2
LK - Sri Lanka 2
NO - Norvegia 2
RS - Serbia 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
LT - Lituania 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
PL - Polonia 1
PT - Portogallo 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 4.004
Salva come PNG Salva come JPEG
Città #
Chandler 375
Fairfield 276
Ashburn 252
Singapore 208
Medford 122
Wilmington 115
Altamura 114
Palermo 93
Princeton 79
Lawrence 77
Cambridge 76
Houston 64
San Diego 64
Dublin 61
Woodbridge 45
Santa Clara 43
Milan 39
Seattle 34
Toronto 33
Rome 31
London 30
Ann Arbor 29
Nuremberg 22
Beijing 19
Tallinn 19
Brussels 13
Kilburn 12
New York 12
Shanghai 12
Vienna 12
Catania 11
Helsinki 11
Naples 11
Saint Petersburg 11
Florence 10
Ludwigshafen am Rhein 10
Turin 10
Boardman 9
Hong Kong 9
Lappeenranta 9
Noto 9
San Paolo di Civitate 9
Abbiategrasso 8
Chicago 8
Tokyo 8
Vicenza 8
West Jordan 8
Edinburgh 7
Hounslow 7
Munich 7
Phoenix 7
Bari 6
Forest City 6
Guangzhou 6
Piscataway 6
Abidjan 5
Castrovillari 5
Central 5
Central District 5
Dallas 5
Frankfurt am Main 5
Los Angeles 5
Norwalk 5
Redwood City 5
Sciara 5
Stockholm 5
Auckland 4
Bremen 4
Caserta 4
Catanzaro 4
Clearwater 4
Council Bluffs 4
Modena 4
Moscow 4
Mumbai 4
Novara 4
Romainville 4
São Paulo 4
Washington 4
Apo 3
Aversa 3
Barletta 3
Bonn 3
Cagliari 3
Cavallino 3
Cingoli 3
Columbus 3
Corropoli 3
Falkenstein 3
Inzai 3
Kerken 3
Kiev 3
Kowloon 3
Melilli 3
Mendicino 3
Mountain View 3
Ponzano Veneto 3
Sasso Marconi 3
Springfield 3
Verona 3
Totale 2.762
Salva come PNG Salva come JPEG
Nome #
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation 132
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 107
Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing 95
Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again 88
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 83
Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome 80
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients 69
Immune Cells, Cytokines, and Gut Microbiota Landscape Along Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Evolution 67
Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 67
Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report 62
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 61
Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev) 60
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: Do we still need it? 59
Mechanisms of immune evasion in multiple myeloma: Open questions and therapeutic opportunities 59
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma 58
Could PD-1/PDL1 immune checkpoints be linked to HLA signature? 58
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility 57
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 56
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 55
COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm 55
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis 54
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma 54
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 53
A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells 53
OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes 53
B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma 52
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 52
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 52
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 50
Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report 50
Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates 50
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 49
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 49
miR-22 suppresses DNA ligase III addiction in multiple myeloma 49
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 49
Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response 49
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy 49
Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer 48
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients 48
The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response 48
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients 48
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients 48
Network meta-analysis of randomized trials in multiple myeloma efficacy and safety in frontline therapy for patients not eligible for transplant 48
Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma 47
Mouse models of multiple myeloma: Technologic platforms and perspectives 47
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 47
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 47
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 47
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 46
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma 46
A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma 46
Tumor infiltration by chemokine receptor 7 (CCR7)+ T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer 45
Immunologic characterization of COVID-19 patients with hematological cancer 45
Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients 45
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 45
Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro 44
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients 44
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 44
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 43
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 43
A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 43
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab 41
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine 41
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients 40
Immunotherapy of colorectal cancer: New perspectives after a long path 40
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells 40
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma 39
Myeloid derived suppressor cells in multiple myeloma: Preclinical research and translational opportunities 39
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma 39
Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation 39
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 39
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 39
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 38
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials 37
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 37
Immunomodulatory activity of microRNAs: Potential implications for multiple myeloma treatment 36
Unveiling Novel Therapeutic Targets for CAR Therapy in Multiple Myeloma through Single-Cell RNA Sequencing 35
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies 35
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse 34
MIR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 34
Immunologic microenvironment and personalized treatment in multiple myeloma 33
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination 33
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients 33
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials 32
Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials 32
Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma 31
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 31
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 30
Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice 29
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in relapsed/refractory patients 28
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma 27
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma 25
Multiple Myeloma in 2023 Ways: From Trials to Real Life 23
Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients 21
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma 20
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 19
AURKA targeting: a NEAT approach to halt myeloma 18
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance 17
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 17
Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant eligible newly diagnosed multiple myeloma: a multicentre real-world experience 14
Totale 4.632
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.954
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.954
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021774 0 0 0 0 0 0 0 0 9 4 19 742
2021/2022912 56 131 28 27 23 76 44 43 100 153 61 170
2022/20231.378 109 247 94 112 146 182 21 137 152 18 118 42
2023/2024766 46 116 57 122 68 75 69 56 23 30 10 94
2024/2025813 55 148 96 164 64 108 137 41 0 0 0 0
Totale 4.643